Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: Subanalysis of the EMPA-REG OUTCOME randomised trial
Diabetologia - Clinical and Experimental Diabetes and Metabolism | Jul 11, 2018
Comparison of single vs dual antiplatelet therapy after TAVR: A systematic review and meta-analysis
Catheterization and Cardiovascular Interventions | Jun 24, 2018
Predictors of residual tricuspid regurgitation after percutaneous closure of atrial septal defect
European Heart Journal – Cardiovascular Imaging | Jun 21, 2018
Most read this week